Recently, ex-vivo gene therapy using a lentiviral vector encoding the human ARSA gene in autologous CD34+ hematopoietic stem and progenitor cells had been approved for the treatment of early stages of late infantile or early juvenile MLD [27, 28]. This evidence concerns the gene ARSA and metachromatic leukodystrophy.